{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:31:37Z","timestamp":1745854297141,"version":"3.37.3"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1124\/jpet.121.000769","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T16:31:06Z","timestamp":1633105866000},"page":"400-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone\u2013Inhibitory Effect of Octreotide after Growth Hormone\u2013Releasing Hormone Stimulation"],"prefix":"10.1016","volume":"379","author":[{"given":"Hiroyuki","family":"Iida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Komagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Shono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junsaku","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Ogawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiteru","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.121.000769_bib1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12020-012-9668-1","article-title":"Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study","volume":"42","author":"Beglinger","year":"2012","journal-title":"Endocrine"},{"key":"10.1124\/jpet.121.000769_bib2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.mce.2007.11.024","article-title":"Somatostatin agonists for treatment of acromegaly","volume":"286","author":"Ben-Shlomo","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/jpet.121.000769_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2265.2008.03481.x","article-title":"Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD)","volume":"70","author":"Berg","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1124\/jpet.121.000769_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1172-3-17","article-title":"Acromegaly","volume":"3","author":"Chanson","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"10.1124\/jpet.121.000769_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003088-199325050-00004","article-title":"Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours","volume":"25","author":"Chanson","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.121.000769_bib6","doi-asserted-by":"crossref","first-page":"E163","DOI":"10.1152\/ajpendo.00334.2002","article-title":"Pulsatile and nocturnal growth hormone secretions in men do not require periodic declines of somatostatin","volume":"285","author":"Dimaraki","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/jpet.121.000769_bib7","doi-asserted-by":"crossref","first-page":"E489","DOI":"10.1152\/ajpendo.2001.280.3.E489","article-title":"Generation of growth hormone pulsatility in women: evidence against somatostatin withdrawal as pulse initiator","volume":"280","author":"Dimaraki","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/jpet.121.000769_bib8","first-page":"857","article-title":"Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide","volume":"54","author":"Doi","year":"2004","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/jpet.121.000769_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/gast.2001.20892","article-title":"Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension","volume":"120","author":"Escorsell","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.121.000769_bib10","unstructured":"Food and Drug Administration (2003) Guidance for industry. Exposure-response relationships \u2014 study design, data analysis, and regulatory applications. https:\/\/www.fda.gov\/media\/71277\/download"},{"key":"10.1124\/jpet.121.000769_bib11","unstructured":"Food and Drug Administration (1998) Drug approvals and databases for Sandostatin lar depot (octreotide acetate) injection. Application No.: 021-008. Clinical pharmacology biopharmaceutics review(s). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/021008a_clinphrm.pdf"},{"key":"10.1124\/jpet.121.000769_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"10.1124\/jpet.121.000769_bib13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1124\/jpet.121.000769_bib14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1124\/jpet.121.000769_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/0091270011399761","article-title":"Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1","volume":"52","author":"Garrido","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.121.000769_bib16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1124\/jpet.121.000769_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/DDDT.S29125","article-title":"A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers","volume":"6","author":"Golor","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/jpet.121.000769_bib18","doi-asserted-by":"crossref","first-page":"13869","DOI":"10.1074\/jbc.272.21.13869","article-title":"Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor","volume":"272","author":"Hipkin","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.121.000769_bib19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/EJE-07-0631","volume":"157","author":"Ho","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1124\/jpet.121.000769_bib20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.121.000769_bib21","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1210\/jc.2004-0205","article-title":"Activation of somatostatin-receptor subtype-2\/-5 suppresses the mass, frequency, and irregularity of growth hormone (GH)-releasing peptide-2-stimulated GH secretion in men","volume":"89","author":"Iranmanesh","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.121.000769_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0090-9556(25)08843-9","article-title":"Disposition of Sandostatin, a new synthetic somatostatin analogue, in rats","volume":"17","author":"Lemaire","year":"1989","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.121.000769_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clpt.2005.04.003","article-title":"Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly","volume":"78","author":"Ma","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.121.000769_bib24","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1373\/clinchem.2012.188128","article-title":"Automated 22-kD growth hormone-specific assay without interference from Pegvisomant","volume":"58","author":"Manolopoulou","year":"2012","journal-title":"Clin Chem"},{"key":"10.1124\/jpet.121.000769_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ghir.2017.07.002","article-title":"Gender has to be taken into account in diagnosing adult growth hormone deficiency by the GHRH plus arginine test","volume":"35","author":"Markkanen","year":"2017","journal-title":"Growth Horm IGF Res"},{"key":"10.1124\/jpet.121.000769_bib26","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.121.000769_bib27","unstructured":"Pharmaceuticals and Medical Devices Agency (2020) Guideline for exposure-response analysis of drugs. https:\/\/www.pmda.go.jp\/files\/000235382.pdf"},{"key":"10.1124\/jpet.121.000769_bib28","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1210\/jc.2003-030303","article-title":"Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion","volume":"88","author":"Ren","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1124\/jpet.121.000769_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","article-title":"Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors","volume":"80","author":"Schmid","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1124\/jpet.121.000769_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1124\/jpet.121.000769_bib31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.12698","article-title":"Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers","volume":"80","author":"Tiberg","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.121.000769_bib32","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1210\/endo.143.4.8716","article-title":"Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment","volume":"143","author":"Tulipano","year":"2002","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.121.000769_bib33","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.121.000769_bib34","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1210\/jc.2003-031052","article-title":"A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients","volume":"89","author":"van der Hoek","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.121.000769_bib35","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1210\/en.2002-220219","article-title":"SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone\/insulin-like growth factor-I axis in rats, primates, and dogs","volume":"143","author":"Weckbecker","year":"2002","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.121.000769_bib36","doi-asserted-by":"crossref","first-page":"e1143544","DOI":"10.1080\/21688370.2016.1143544","article-title":"Heterogeneity of the blood-brain barrier","volume":"4","author":"Wilhelm","year":"2016","journal-title":"Tissue Barriers"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.121.000769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:03:02Z","timestamp":1739973782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524270919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0022356524270919"],"URL":"https:\/\/doi.org\/10.1124\/jpet.121.000769","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone\u2013Inhibitory Effect of Octreotide after Growth Hormone\u2013Releasing Hormone Stimulation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.121.000769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}